
|Articles|June 3, 2015
Bringing a Biologic from the Bench to the Marketplace
Author(s)Randi Hernandez
Michiel E. Ultee of Ulteemit BioConsulting discusses converting an early drug discovery into a product that is ready for clinical testing.
Advertisement
In this video, Michiel E. Ultee, PhD, principal of Ulteemit BioConsulting, discusses converting an early drug discovery into a product that is ready for clinical testing, biologics license applications, and FDA guidance documents.
The video was shot at INTERPHEX 2015 in New York, NY.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5




